After FDA Rejection, Disc Medicine’s EPP Drug Hits All Goals in Phase 3 Trial
Disc Medicine’s bitopertin succeeded on all primary and secondary endpoints in the APOLLO Phase 3 trial, sending the stock sharply higher.
Disc Medicine’s bitopertin succeeded on all primary and secondary endpoints in the APOLLO Phase 3 trial, sending the stock sharply higher.
Disc Medicine's bitopertin gets turned down by FDA for treating EPP, a painful genetic condition making skin ultra-sensitive to sun.
FDA extends review timelines for Eli Lilly's obesity pill Orforglipron and three other priority voucher drugs, despite promises of accelerated 1-2 month reviews under new program.
Disc Medicine (IRON) shares fall 14% after FDA official questions bitopertin's effectiveness for rare blood disorder, though analysts maintain buy ratings and approval pathway optimism.
Disc Medicine receives FDA's Commissioner's National Priority Voucher for bitopertin, accelerating approval timeline to 1-2 months for EPP patients who suffer severe sun sensitivity.